BDR Pharmaceuticals has introduced the Enzalutamide oral solution, BDENZA, for prostate cancer treatment.. The new solution is more effective, soothing on the stomach, sugar-free, and tasty, making it more patient-friendly and cheap. The Drug Controller General of India approves the drug delivery mechanism.
BDR Pharmaceuticals announced on Tuesday that it is the first business to introduce Enzalutamide oral solution for prostate cancer treatment with the innovative medication delivery technology.
BDR Pharmaceuticals announced the launch of BDENZA, a 32 mg/ml oral enzalutamide solution priced at Rs 27,000 for 150ml.
It noted that this novel formulation of Enzalutamide provides an effective dose form with fewer side effects than current oral dosage forms.
BDENZA oral solution improves prostate cancer treatment with a variety of benefits. One 5 ml dosage provides 160 mg, therefore there’s less difficulty with plenty of tablets “Aravind Badiger, BDR Pharmaceuticals Director, Technical Formulation, remarked.
Doctors can tailor dosages to patients, unlike fixed-dose tablets. This oral solution is stomach-friendly, preventing nausea.
He said that it is sugar-free and tastes nice, making it simpler for patients, especially those with taste alterations or dietary restrictions, to stay to the treatment.
This prostate cancer treatment is more patient-friendly. It can greatly increase patient compliance, Badiger said.
The company said the DCGI-approved new drug delivery system will make it cheaper and more accessible in India.
“BDENZA revolutionizes prostate cancer treatment. Its launch supports our mission to provide accessible, patient-centered healthcare “Raheel Shah, BDR Group Director (Business Development), said.
Conclusion
BDR Pharmaceuticals’ BDENZA oral enzalutamide solution treats prostate cancer. The novel formulation is more effective and has fewer negative effects than oral dosing forms. BDENZA 150ml costs Rs 27,000 and delivers 160mg in 5ml. It is soft on the stomach, sugar-free, and tasty, making it easier for individuals with taste alterations or dietary restrictions to follow treatment. The Drug Controller General of India-approved distribution system will make it cheaper and more accessible in India.
